Ultragenyx Pharmaceutical

RAREleader

Ultragenyx is a rare-disease biopharmaceutical company with multiple approved therapies and a gene therapy pipeline, focusing on metabolic and bone diseases with no or limited treatment options.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($652M)

Data statis (memuat keuangan langsung…)

Crysvita Royalties + Direct (60%)

Other Products (40%)

Komposisi segmen dan pelanggan utama

Detail produk

Mepsevii (MPS VII)18%

IV enzyme replacement therapy for mucopolysaccharidosis VII — ultra-rare metabolic disorder.

Crysvita (XLH / TIO)45%

Burosumab monoclonal antibody for X-linked hypophosphatemia, the most common inherited form of rickets.

GTX-102 / setrusumab (bone diseases)15%

Gene therapy pipeline targeting osteogenesis imperfecta (brittle bone disease) and related disorders.

UX111 / delandistrogene (UCD, other)22%

AAV gene therapy programs for rare liver-based metabolic disorders and DMD.

Hubungan Rantai Pasok

Mitra

kyowa

Crysvita (burosumab) co-development

Dampak: critical

Konteks makro dan pasar

헬스케어Berita sektor

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Katalis mendatang

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Ultragenyx Pharmaceutical.

Info Perusahaan

Kantor Pusat

Novato, California, USA

Didirikan

2010

Karyawan

1,200

Situs Web

ultragenyx.com

Gambaran umum sektor — 헬스케어

Berita sektor